Safe and successful transition from oral selexipag to subcutaneous treprostinil in a patient with idiopathic pulmonary arterial hypertension treated with triple combination therapy-Reference-Cited by-同舟云学术

Safe and successful transition from oral selexipag to subcutaneous treprostinil in a patient with idiopathic pulmonary arterial hypertension treated with triple combination therapy

Published:2022-07 Issue:1 Volume:26 Page:42-45
ISSN:1878-5409
Container-title:Journal of Cardiology Cases
language:en
Short-container-title:Journal of Cardiology Cases

Author:

Adachi Shiro,Nishiyama Itsumure,Yasuda Kenichiro,Yoshida Masahiro,Nakano Yoshihisa,Kondo Takahisa,Murohara Toyoaki

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference7 articles.

1. Selexipag for the treatment of pulmonary arterial hypertension;Sitbon;N Engl J Med,2015

2. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival;Sitbon;J Am Coll Cardiol,2002

3. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil;Barst;Eur Respir J,2006

4. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. A double-blind, randomized, placebo-controlled trial;Simonneau;Am J Respir Crit Care Med,2002

5. Transitioning from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension;Vachiéry;Chest,2002

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A real-world analysis of safety profile of selexipag by using FDA adverse Event Reporting System (FAERS);Expert Opinion on Drug Safety;2023-11-30

2. Transitioning intravenous epoprostenol to oral selexipag in idiopathic pulmonary arterial hypertension: a case report;ESC Heart Failure;2023-06-19